A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.
Individuals with obstructive sleep apnoea (OSA) may have an increased risk of COVID-19, with the risk reducing with adherence to positive airway pressure (PAP) therapy, according to a study presented at ATS 2021.
A recent European survey has found major discrepancies and gaps in hospital policies and procedures to prevent the direct transmission of hepatitis B virus (HBV) from mother to child, particularly before and after birth.
Adding the sodium-glucose cotransporter-2 (SGLT2) inhibitor henagliflozin to metformin led to significant improvements in glycaemic control, body weight, and blood pressure (BP) in Chinese patients with type 2 diabetes (T2D) with insufficient response to metformin alone, a phase III study has shown.
Antidepressants remain the most understood treatment modality for depression after coronary artery disease (CAD), though emerging evidence suggests that combining them with psychotherapy and exercise seems to improve effectiveness, according to a recent network meta-analysis.
In hospitalized COVID-19 patients with elevated D-dimer levels who were under stable condition, initial in-hospital anticoagulation using a therapeutic dose of rivaroxaban 20 mg did not improve clinical outcomes compared with standard prophylactic anticoagulation, according to the ACTION* trial presented at ACC.21 Meeting.
The REGN-COV2 monoclonal antibody cocktail comprising casirivimab and imdevimab significantly reduces the risk of hospitalization and all-cause death by 71 percent compared with placebo in nonhospitalized patients with COVID-19, according to a large phase III study presented at the ATS 2021 Meeting.
In obese patients without gallstones, a 6-month treatment course of ursodeoxycholic acid (UDCA) following bariatric surgery may reduce their likelihood of developing symptomatic gallstones, according to findings of the UPGRADE trial from The Netherlands presented at DDW 2021.